SGS enhances bioanalytical capacity with Saint-Benoît laboratory expansion

Supporting complex drug development programs worldwide

BAAR, SWITZERLAND, August 13, 2026 /EINPresswire.com/ — SGS, the world’s leading testing, inspection and certification company, has expanded its Saint-Benoît laboratory, a strategic site dedicated to pharmaceutical bioanalysis and drug development for the pharmaceutical and biotechnology industries. Located near Poitiers, France, the laboratory has been recognized as a key player for more than 35 years, supporting clients throughout the development of their preclinical and clinical programs.

The expansion adds 500 m² to the Saint-Benoît site and, combined with the renovation of existing facilities, brings its total footprint to nearly 4,500 m² of modernized laboratory space. Designed to support the evolving needs of pharmaceutical and biotechnology companies, the investment enhances analytical capabilities, accommodates growing sample volumes and enables the management of increasingly complex programs. The site now benefits from advanced technologies and optimized workflows that support the continued growth of its bioanalytical activities.

The Saint-Benoît laboratory supports clients throughout the drug development lifecycle, from the preclinical phase to clinical trials. Its services include:
• Quantification of small molecules, monoclonal antibodies, biologics, ADCs, RNAs, etc.
• Pharmacokinetic (PK) and pharmacodynamic (PD)
• Immunogenicity testing
• Biomarker assessment
• Radioimmunoassay

All activities are performed in accordance with international GCP and GLP standards, generating reliable, high-quality data to support development and regulatory requirements.

Through this expansion, SGS has further strengthened its ability to support large-scale and increasingly complex studies while maintaining high standards of quality and turnaround times. Increased operational capacity and flexibility help clients manage project timelines more effectively and accelerate the development of innovative therapies across a range of therapeutic areas, including oncology and infectious diseases.

The Saint-Benoît laboratory continues to invest in innovation through automation, digitalization and collaboration with academic partners, including the University of Poitiers. These initiatives strengthen scientific excellence, support the development of technical capabilities and contribute to training the next generation of life sciences professionals.

Walid Elbast, Director, Saint-Benoît Laboratory: “This expansion marks an important milestone for the Saint-Benoît laboratory and reinforces our commitment to supporting increasingly complex bioanalytical programs. The investment expands our capacity to manage growing sample volumes, support large-scale studies and deliver the reliable, high-quality data our clients require to advance the development of new therapies.

“Through our strong ties with local academic and institutional partners, we are also helping to create new opportunities for future scientists in an environment focused on innovation and excellence.”

This investment reflects SGS’s ongoing commitment to expanding its pharmaceutical and bioanalytical capabilities to support the development of innovative therapies. It further strengthens SGS’s ability to provide scientific solutions that help clients bring safe and effective medicines to patients faster.

Ruth Roy
Sugarloaf Marketing
ruth@sugarloafmarketing.com

Media gallery